Question: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Constraint: The Compound can be represented with the SMILES NC(=O)c1ccc(I)c([N+](=O)[O-])c1.
Answer: Phase 3 Clinical Trials
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
NC(=O)c1ccc(I)c([N+](=O)[O-])c1
NC(=O)c1ccc(I)c([N+](=O)[O-])c1
4-iodo-3-nitrocyclohexa-1,3,5-triene-1-carboxamide
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.